Best responses to pomalidomide, ixazomib, clarithromycin, and dexamethasone. Proportion of responses to ClIPd therapy in the total cohort and stratified by cytogenetic risk. High-risk cytogenetics were considered +1q (either gain or amplification), del(17p), t(4;14) or t(14;16).